NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $3,317,000 | +9.3% | 169,656 | -28.3% | 0.23% | +30.7% |
| Q2 2014 | $3,035,000 | -19.5% | 236,737 | -23.9% | 0.18% | -42.4% |
| Q1 2014 | $3,772,000 | +25.5% | 311,285 | +17.6% | 0.31% | +35.8% |
| Q4 2013 | $3,005,000 | +6.4% | 264,757 | -2.1% | 0.23% | -2.6% |
| Q3 2013 | $2,824,000 | -11.9% | 270,374 | -2.6% | 0.24% | -21.1% |
| Q2 2013 | $3,205,000 | – | 277,513 | – | 0.30% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |